Patients with cholestatic disease have increased systemic concentrations of bile acids (BAs) and profound pruritus. The G protein-coupled BA receptor 1 TGR5 (encoded by GPBAR1) is expressed by primary sensory neurons; its activation induces neuronal hyperexcitability and scratching, by unknown mechanisms. We investigated whether the transient receptor potential ankyrin 1 (TRPA1) is involved in BA-evoked, TGR5-dependent pruritus in mice.
Introduction
Itch induces the protective reflex of scratching that removes irritants and parasites from the skin.
However, chronic itch that is associated with disease (e.g., hepatic, renal, neurological disorders, eczema, certain cancers) is debilitating, poorly understood and difficult to treat 1 . A deeper understanding of the mechanisms of disease-associated itch is required to develop more effective therapies.
Pruritogens induce itch by activating G protein-coupled receptors (GPCRs) and transient receptor potential (TRP) ion channels on cutaneous afferent nerve endings. Histamine from mast cells activates the histamine H 1 receptor that, via phospholipase-C (PLC) signaling, sensitizes TRP vanilloid 1 (TRPV1), which is necessary for neuronal excitation and scratching 2 . Although antagonists of the H 1 receptor are useful therapies for this acute allergic itch, anti-histamines are ineffective for chronic itch. Pruritogens that induce histamine-independent itch include the anti-malarial drug chloroquine, which activates the Masrelated GPCR MrgprA3, the endogenous peptide pruritogen BAM8-22, which activates MrgprC11 3 , and proteases that activate protease-activated receptor-2 4 . MrgprA3 and MrgprC11 respectively activate Gβγ and PLC signaling pathways that sensitize TRP ankyrin 1 (TRPA1), which is required for the acute excitatory and pruritogenic actions of chloroquine and BAM8-22 5 . TRPA1 is also necessary for the exacerbated scratching of mice with dry skin 6 . However, the contribution of TRPA1 to acute and chronic itch that is induced by disease-relevant endogenous pruritogens has not been studied, and the contribution of TRPA1 to the release of neuropeptides that transmit itch, including gastrin-releasing peptide (GRP) 7 and natriuretic polypeptide B (NPPB) 8 , is unknown.
We recently identified the bile acid (BA) GPCR TGR5 as a major mediator of BA-evoked scratching in mice 9 . Patients with cholestatic liver disease, which is characterized by deficient bile secretion into the intestine, can develop chronic pruritus that is so severe and intractable that it is an indication for liver transplantation 10 . BAs may cause cholestatic pruritus since BA levels are increased in the circulation 11 and skin 12 of patients with cholestasis, BA chelators relieve cholestatic pruritus 13 , and application of BAs to the skin causes itch 14 . TGR5 is expressed by primary afferent neurons, and BAs induce neuronal excitability, stimulate release of GRP in the spinal cord, and evoke scratching by TGR5dependent mechanisms 9 . The role of TRPA1 in BA-evoked itch is unexplored.
M A N U S C R I P T
A C C E P T E D ACCEPTED MANUSCRIPT 5 two-electrode voltage-clamp 17 . AITC (50 µM) and HC-030031 (15 µM) were used to activate and inhibit TRPA1 currents, respectively. DCA (500 µM) was used to activate TGR5.
Neuropeptide release. Slices of rat spinal cord with attached dorsal roots (combined cervical, thoracic, lumbar-sacral segments) were prepared and superfused with Krebs solution 9 . Slices were stimulated with TLCA (500 µM), AITC (100 µM) or vehicle for 60 min. Some tissues were superfused with HC-030031 (50 µM) or vehicle wiping behavior. for 20 min before and during the stimulus. GRP and NPPB release were determined by enzyme immunoassays, and peptide concentrations were calculated as fmol.g-1 tissue wet weight. c-fos in spinal neurons. Mice were sedated (isoflurane) and DCA (25 µg, 10 µl, s.c.) or vehicle (0.9% NaCl) was injected into the nape of the neck. They were either allowed to recover from sedation of were kept sedated to exclude scratching-induced activation of spinal neurons. Some groups were pretreated with HC-030031 (100 mg.kg -1 p.o.) or vehicle (100 µl) 30 min before DCA. At 60 min after DCA, mice were anesthetized and transcardially fixed. Frozen sections of cervical spinal cord were made and processed to detect β-galactosidase 18 . β-galactosidase (c-fos) -positive cells in dorsal horn laminae I-III were counted by an observer unaware of the treatment.
Scratching and nociception.
Behavior was assessed in mice by an investigator unaware of treatment groups 9, 19 . Mice were sedated (isoflurane) and DCA (25 µg, 10 µl, s.c.) was injected into the nape of the neck. Some groups were pretreated with HC-030031 (100 mg.kg -1 , p.o., in 2% DMSO, 20% cyclodextrin), AMG-9810 (40 mg.kg -1 , i.p., in 0.9% saline) or vehicle (100 µl) 30 min before DCA injection. Scratching behavior was recorded ~2 h after food withdrawal for 60 min after DCA injection 9 . The effectiveness of AMG-9810 as a TRPV1 antagonist was determined by its capacity to suppress pain-related wiping behavior in response to capsaicin (3 µg, 10 µl, s.c.) into the cheek 19 .
BA sequestrant. Tgr5-tg mice were treated with the BA sequestrant colestipol hydrochloride (2.5 mg.kg -1 , p.o.) or vehicle (0.9% NaCl, p.o.) at 08:00 and 14:00 h for 5 days. After the final dose spontaneous scratching behavior was recorded for 60 min. Some mice received HC-030031 (100 mg.kg -1 ) or vehicle 30 min before scratching behavior was recorded.
Plasma BAs. Tgr5-tg mice treated with colestipol or vehicle were killed at the end of the scratching assays.
Blood was collected at ~4 h after food withdrawal by cardiac puncture for assay of total plasma BAs.
Statistics.
Results are expressed as mean±SEM. Data were compared statistically using a Student's t-test (2 groups) or ANOVA and Bonferroni or Tukey-Kramer post hoc test (multiple groups). P<0.05 was considered significant.
Results

TGR5 is co-expressed with TRPA1 in a population of primary afferent neurons that innervate the skin.
M A N U S C R I P T
A C C E P T E D ACCEPTED MANUSCRIPT 6 To identify dorsal root ganglia (DRG) neurons that innervate the skin, we injected the retrograde tracer DiI intradermally (nape of neck) in mice. TGR5 was detected using an antibody that specifically detects TGR5 in small diameter neurons of wild-type but not tgr5 -/mice 9 . TGR5 and the pan-neuronal markers NeuN or Hu-C/D were localized by immunofluorescence, and TRPA1 was detected by in situ hybridization. All DiI-containing cells expressed NeuN immunoreactivity (IR) or Hu-C/D-IR, and are thus neurons ( Fig. 1 ). TGR5-IR was detected in a sub-population of small diameter (<25 µm) neurons that contained DiI, although some DiI-containing neurons did not express TGR5-IR ( Fig. 1A, B ). Of the DiIcontaining neurons, 18.2±2.4% expressed TGR5-IR and 81.8±2.4% did not express detectable TGR5 (889 neurons, n=6 mice) ( Fig. 1B ). TGR5-IR and TRPA1 mRNA were colocalized in a proportion of DiIcontaining neurons (Fig. 1C ). TRPA1 mRNA was detected in 20.5±1.4% and TGR5-IR and TRPA1 mRNA were co-expressed in 4.2±0.4% of all DRG neurons (1850 neurons, n=6 mice) ( Fig. 1D ). TRPA1 mRNA was detected in 28.3±3.2% and TGR5-IR and TRPA1 mRNA were co-expressed in 7.0±0.7% of cutaneous afferent neurons ( Fig. 1D ). By using single cell RT-PCR, we detected transcripts corresponding to TGR5 (236 bp), TRPA1 (393 bp) and TRPV1 (229 bp) in DiI-containing neurons ( Fig. 1E ). Analysis of 60 small diameter DiI-containing neurons from 6 mice revealed that 37% (22/60) expressed TRPV1, 20% (12/60) expressed TRPA1, and 8% (5/60) expressed TGR5 ( Fig. 1F ). All TGR5-positive neurons (5/5) coexpressed TRPA1.
TGR5 activates and sensitizes TRPA1 in HEK293 cells by a Gβγ βγ βγ
βγand protein kinase C-mediated mechanism. To examine the functional interactions between TGR5 and TRPA1, we expressed in HEK293 cells TGR5 and TRPA1 separately or together. We assessed TRPA1 activation by measuring [Ca 2+ ] i . Cells were challenged with vehicle or deoxycholic acid (DCA, 100 µM), a TGR5 agonist, and 5 min later were stimulated with the TRPA1 agonist AITC (100 µM). In HEK-TGR5 cells, vehicle, DCA or AITC did not affect [Ca 2+ ] i ( Fig. 2A , E, F). In contrast, in HEK-TGR5+TRPA1 cells, DCA but not vehicle induced a prompt increase in [Ca 2+ ] i ( Fig. 2A , E). The response of HEK-TGR5+TRPA1 cells to AITC was larger in cells pretreated with DCA when compared to vehicle ( Fig. 2A 2D, E, F). PKA may desensitize TGR5, which couples to cAMP and PKA 22 .
TGR5 stimulates TRPA1 currents in Xenopus laevis oocytes.
In oocytes expressing TRPA1 alone or TRPA1 and TGR5, AITC (50 µM) elicited a transient inward current that was prevented or reversed by HC-030031 (15 µM) consistent with activation of TRPA1 ( Fig. 3A, B ). To determine whether activation of TGR5 sensitizes TRPA1 currents, oocytes co-expressing TRPA1 and TGR5 were exposed to DCA (500 µM) or vehicle (control) for 30 s prior to AITC. Pre-incubation with DCA resulted in a ~40% increase of the AITC-evoked TRPA1 current compared to vehicle-treated oocytes ( Fig. 3C ). In contrast, DCA did not increase the AITC current response in oocytes expressing TRPA1 alone. Thus, the stimulatory effect of DCA on TRPA1 currents requires co-expression of TGR5, and DCA does not directly activate TRPA1.
Chelation of intracellular Ca 2+ ions using BAPTA-AM (100 µM) prevented DCA-evoked sensitization of TRPA1, which is Ca 2+ -dependent ( Fig. 3D ). BAPTA-AM increased the baseline AITC response by unknown mechanisms. GF109203X, but not gallein, also inhibited the AITC response in neurons, but neither affected to capsaicin response. In neurons from trpv1 -/mice, the responses to AITC and DCA were preserved, whereas the response to capsaicin was absent ( Fig. 4F; Supplemental Fig. 2D ). Trpv1 deletion reduced the proportion of DCA-responsive neurons, but the change was not significant.
TGR5 activates TRPA1 in primary afferent neurons by a
In wild-type mice, 33.3±6.2% of AITC-responsive neurons also responded to DCA. Moreover, 27 .1±5.6% of wild-type neurons responded to AITC, DCA and capsaicin, whereas 6.2±2.1% of neurons responded to AITC and DCA but not capsaicin ( Fig. 5A ). Removal of extracellular Ca 2+ ions suppressed responses to AITC, DCA and capsaicin ( Fig. 5B ). Deletion of TGR5 and deletion or antagonism of TRPA1 abolished responses to DCA ( Fig. 5C , D, E). TRPA1 deletion and antagonism also blocked responses to AITC ( Fig. 5D , E). In wild-type mice, 32.8±7.8% of neurons responded to AITC, TLCA and capsaicin, whereas 6.8±1.4% of neurons responded to AITC and TLCA but not capsaicin ( Fig. 5F ).
Thus, DCA and TLCA stimulate TGR5, which activates TRPA1 via Gβγ and PKC to promote the influx of extracellular Ca 2+ ions in small diameter DRG neurons of mice. 
BAs induce TRPA1-dependent release of the itch transmitters GRP and NPPB. Pruritogens
Discussion
Our results reveal an essential role for TGR5-induced activation of TRPA1 for the pruritogenic actions of exogenous and endogenous BAs. We report that TGR5 and TRPA1 are co-expressed by a sub- resembles MrgprA3 and MrgprC11, which also activate TRPA1 to induce itch 5 .
A key finding is that the BA sequestrant colestipol inhibits exacerbated spontaneous scratching in gain-of-function tgr5-tg mice. BAs that are secreted into the intestinal lumen during feeding are absorbed in the ileum and colon, and the circulating levels of BAs wax and wane during feeding and fasting 26 . Our observation that treatment of tgr5-tg mice with a BA sequestrant reduced both spontaneous scratching and circulating BA levels by ~ 50% suggests that endogenous BAs are sufficient to drive exacerbated scratching in mice that overexpress TGR5. HC-030031 reduced spontaneous scratching of tgr5-tg mice to that observed under basal conditions in wild-type mice, which reveals a requirement for TRPA1 for the pruritogenic actions of endogenous BAs.
Contributions of BAs, TGR5 and TRPA1 to cholestatic pruritus. The contribution of BAs to cholestatic
pruritus is debatable. There are increased circulating and tissue levels of BAs in cholestatic patients 11, 12 , injection of BAs into the skin causes scratching in humans 14 , and BA sequestrants are a treatment for cholestatic pruritus 13 . However, scratching severity does not correlate with circulating BAs levels in patients with cholestatic disease, and other factors have been implicated in cholestatic itch, including lysophosphatidic acid and opioids 29, 30 . Our finding that tgr5-tg mice exhibit spontaneous pruritus that depends on endogenous BAs suggests that the pathological upregulation of TGR5 alone, in the absence of elevated levels of BAs, may be sufficient to induce pruritus. Whether TGR5 is upregulated in patients with pruritus remains to be examined. We found that TRPA1 antagonism prevents exacerbated scratching of tgr5-tg mice. Thus, TRPA1 antagonists, in addition to TGR5 antagonists, may be considered to be new treatments for pruritus that accompanies liver diseases and other conditions such as pregnancy, where certain upregulated progesterone metabolites may also activate TGR5 31 . These possibilities deserve further attention. Given intractable nature of the severe pruritus that accompanies hepatic diseases, potentially leading to liver transplantation, the TGR5/TRPA1 pathway may be a therapeutic target for the histamine-independent chronic itch in which BAs are involved. tetracycline-free fetal bovine serum (FBS), blasticidin (5 µg.ml -1 ) and hygromycin (100 µg.ml -1 ). To generate cells co-expressing TRPA1 and TGR5, human TGR5 was cloned into pcDNA3.1 neo and then co-transfected into the HEK-TRPA1 cells using a calcium phosphate-DNA co-precipitation method. In brief, cells were incubated in 125 mM CaCl 2 plus HBSS with 1 µg TGR5 pcDNA3.1 overnight at 37°C
Figure Legends
and 5% CO 2 . The transfection medium was replaced with selection medium (10% FBS, 5 µg.ml -1 blasticidin, 100 µg.ml -1 hygromycin, 400 µg.ml -1 G418) and single clones isolated by limiting dilution.
The clones were grown under selection, assayed for cAMP responses to the TGR5 agonist DCA, and one clone was selected based on its robust response. Cells were maintained in DMEM containing 10% tetracycline-free fetal FBS, 1% penicillin and streptomycin, 100 µg.ml -1 hygromycin, 400 µg.ml -1 G418 and 5 µg.ml -1 blasticidin. To induce the expression of TRPA1, HEK-TRPA1 and HEK-TRPA1-TGR5 cells were incubated with tetracycline (100 ng.ml -1 ) for 16 h before experiments. investigate the potential functional coupling between TGR5 and TRPA1, cells were challenged with DCA (100 µM, 5 min) and then AITC (100 µM, 5 min). To investigate the mechanism of TGR5 and TRPA1 functional coupling, cells were incubated with H89 (10 µM, PKA inhibitor), GF109203X (10 µM, PKC inhibitor), gallein (100 µM, Gβγ inhibitor), or vehicle (control) (60 min preincubation and inclusion through assays).
Isolation and culture of DRG neurons. DRG were removed from all spinal levels from C57BL/6J, tgr5 -/and trpa1 -/mice, and were dissociated as described 12 . Neurons were plated onto poly D-lysine-(0.1 mg.ml -1 ) and laminin-(0.004 mg.ml -1 ) coated glass coverslips for Ca 2+ assays or onto poly-D-lysine-and laminin-coated 96 well plates for ERK1/2 and cAMP assays. Neurons were cultured for 24 h before assays. 
Measurement of TRPA1 currents in Xenopus laevis oocytes.
Oocytes were collected from Xenopus laevis as described 14 . Defolliculated stage V-VI oocytes were injected (Nanoject II automatic injector, Drummond) with cRNA encoding human TRPA1 alone (0.5 ng) or both TRPA1 (0.5 ng) plus humanTGR5 (2 ng). The cRNAs were dissolved in RNase-free water and the total volume injected was 46 nl. Injected oocytes were stored at 19°C in ND9 solution (mM: N-methyl-D-glucamine-Cl 87, NaCl 9, Wiping behavior was recorded at baseline and for 20 min after capsaicin injection by observers blinded to the experimental protocol. A wipe was defined as a singular motion of the ipsilateral (but not bilateral) forelimb beginning at the caudal extent of the injected cheek and proceeding in a rostral direction.
Treatment of tgr5-tg mice with BA sequestrant and TGR5 antagonist.
To determine the role of endogenous BAs to exacerbated spontaneous scratching, tgr5-tg mice were treated with the BA sequestrant colestipol hydrochloride (2.5 mg.kg -1 , p.o., Pfizer, Groton, CT) or vehicle (0.9% NaCl, p.o.), which were administered by gavage (100 µl) at 08:00 and 14:00 h for five consecutive days. During this treatment period, mice were habituated as described. After the final gavage treatment, spontaneous scratching behavior was recorded for 60 min. To determine the contribution of TRPA1 to exacerbated spontaneous scratching, tgr5-tg mice were treated with HC-030031 (100 mg.kg -1 ) or vehicle 30 min before scratching behavior was recorded. 
Measurement of plasma
